MEI's drug candidate zandelisib is a P13K delta inhibitor. It is being studied in lymphoma in B cells.

Qpex is developing IV and oral drugs to overcome resistance mechanisms in bacteria that render penicillin-like drugs inactive.

I think a lot is being done to address health equity, but yet we have an opportunity to do a lot more.